adalimumab-adaz (Hyrimoz) vs Hemay007
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
adalimumab-adaz (Hyrimoz)
Marketed by Sandoz Group AG and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Hemay007
Developed by Tianjin Hemay Pharmaceutical
NCT02603185 · Phase 1 · status unknown
This is a randomized, double-blind, placebo-controlled early-phase safety and pharmacokinetics study conducted in healthy volunteers rather than in patients with the target condition, with adverse-event monitoring as its primary endpoint rather than a measure of disease benefit. No results have been posted yet. Its registered primary outcome on ClinicalTrials.gov is "Adverse events assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-adaz (Hyrimoz) | Hemay007 |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Not reported |
| Endoscopic response (induction) | —Not reported | —Not reported |
| Clinical remission (maintenance) | —Not reported | —Not reported |
| Endoscopic response (maintenance) | —Not reported | —Not reported |
Clinical remission (induction)
- adalimumab-adaz (Hyrimoz)
- —Not reported
- Hemay007
- —Not reported
Endoscopic response (induction)
- adalimumab-adaz (Hyrimoz)
- —Not reported
- Hemay007
- —Not reported
Clinical remission (maintenance)
- adalimumab-adaz (Hyrimoz)
- —Not reported
- Hemay007
- —Not reported
Endoscopic response (maintenance)
- adalimumab-adaz (Hyrimoz)
- —Not reported
- Hemay007
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-adaz (Hyrimoz): no structured comparison results are available for Crohn's Disease.
Hemay007: no structured comparison results are available for Crohn's Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-adaz (Hyrimoz)'s landscape · Hemay007's landscape